Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why

Core Viewpoint - Structure Therapeutics Inc. (NASDAQ:GPCR) is recognized as one of the top 14 stocks to buy, with shares increasing over 130% in the last three months due to positive developments related to its oral obesity treatment [1][2]. Group 1: Clinical Developments - A study on aleniglipron, an oral obesity pill, showed a weight loss of 11.3% in obese or overweight patients after 36 weeks at a dosage of 120 mg, marking a significant advancement in the market primarily dominated by injectables [2]. - Ongoing clinical research is testing a 240 mg dose of aleniglipron, which has resulted in an even greater weight loss of 15.3% after 36 weeks [3]. - On December 17, the company announced the initiation of the first human trial for ACCG-2671, an oral small-molecule amylin receptor aimed at treating obesity [3]. Group 2: Market Performance and Analyst Ratings - Wall Street analysts maintain a bullish outlook on GPCR, with a consensus Strong Buy rating and a one-year average price target of $104, indicating a potential upside of 49.94% as of January 12 [4]. - Recent analyst updates include a Buy rating from LifeSci Capital with a price target of $107 and an Outperform rating from BMO Capital with a price target of $130 [4]. Group 3: Company Overview - Structure Therapeutics Inc. is a biotechnology company focused on developing treatments for chronic metabolic conditions [5].